Moneycontrol PRO
LAMF
LAMF

Viswanath Pilla

Senior Assistant Editor, Moneycontrol News

Sun Pharma may face tariff turbulence in US but HSBC sees limited earnings risk

BUSINESS

Sun Pharma may face tariff turbulence in US but HSBC sees limited earnings risk

HSBC outlines several mitigation strategies for Sun Pharma, including shifting manufacturing to CDMO partners with US-based plants.

Trump’s 100% drug tariff: A mixed bag for India’s CRDMO industry

BUSINESS

Trump’s 100% drug tariff: A mixed bag for India’s CRDMO industry

“Few Indian pharma companies with exposure to non-U.S. domiciled branded formulation or innovator drug companies, who in turn export to the U.S., may face challenges,” said Deepak Jotwani, VP & Sector Head, ICRA.

Generic medicines exempted from Trump’s 100% pharma tariffs, but uncertainty continues

BUSINESS

Generic medicines exempted from Trump’s 100% pharma tariffs, but uncertainty continues

While generic drugs are exempted from the latest action, companies still face uncertainty over tariffs due to an investigation by the US government under Section 232 to see whether pharma imports pose a threat to national security.

Greying India fuels adult diaper market boom, homegrown Friends leads the way

BUSINESS

Greying India fuels adult diaper market boom, homegrown Friends leads the way

Unlike baby diapers, dominated by FMCG giants such as P&G, Unicharm and Kimberly-Clark, the Rs 1,200-crore adult diaper segment is commanded by Friends with over a 50% market share

Alkem launches pertuzumab biosimilar in India for treatment of breast cancer

BUSINESS

Alkem launches pertuzumab biosimilar in India for treatment of breast cancer

In the pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator, the company said in a press release.

Senior care market poised to triple in a decade, turning the space into the next big investment idea

BUSINESS

Senior care market poised to triple in a decade, turning the space into the next big investment idea

Rising life expectancy, smaller families and growing willingness among seniors to spend on care are creating conditions for a market that could expand several times over in the coming decade.

Stryker expands India R&D with new innovation centre in Bengaluru

BUSINESS

Stryker expands India R&D with new innovation centre in Bengaluru

The Whitefield centre will house cross-functional teams and advanced labs focused on robotics, artificial intelligence, digital innovation, and product security, the company said Thursday.

Dr. Agarwal’s says merger valuation structured through fair and transparent process

BUSINESS

Dr. Agarwal’s says merger valuation structured through fair and transparent process

The swap ratio—23 AHCL shares (Re 1 face value) for every 2 AEHL shares (Rs 10 face value)—was based on independent valuations by PwC and Bansi Mehta & Co., using globally accepted methods and market price trends, says company

Bayer goes big on prenatal nutrition, eyes bigger share of India’s consumer health pie

BUSINESS

Bayer goes big on prenatal nutrition, eyes bigger share of India’s consumer health pie

While leveraging enduring appeal of legacy brands such as Saridon and Supradyn, Bayer is also aggressively pushing into India’s Rs 40,000–45,000 crore consumer health market

Hospitals versus health insurers: Why patients are paying the price

BUSINESS

Hospitals versus health insurers: Why patients are paying the price

Star Health alone logged 13,300 complaints in FY24, over 10,000 of which were claim-related

Dr Reddy’s launches novel acid blocker Tegoprazan in India to tap $1 billion market

BUSINESS

Dr Reddy’s launches novel acid blocker Tegoprazan in India to tap $1 billion market

The rollout follows Dr. Reddy’s exclusive licensing deal with South Korea’s HK inno.N Corp. in 2022 to commercialize Tegoprazan in India and select emerging markets.

India revokes Novartis' patent for blockbuster heart drug

BUSINESS

India revokes Novartis' patent for blockbuster heart drug

Vymada is widely prescribed for hypertension and heart failure. For Novartis, the drug is a major revenue driver, generating $7.8 billion in global sales last year

Brooks Labs looks to exit carbapenem JV, OneSource may buy stake

BUSINESS

Brooks Labs looks to exit carbapenem JV, OneSource may buy stake

This move could provide a significant cash infusion for Brooks, which holds a 49% stake in the joint venture with Steriscience Specialties Pvt. Ltd.

No mandatory relabelling of pre-revised GST stock, NPPA offers ease of compliance to industry

BUSINESS

No mandatory relabelling of pre-revised GST stock, NPPA offers ease of compliance to industry

The National Pharmaceutical Pricing Authority (NPPA) clarified that companies can continue selling pre-GST stock without re-stickering, provided they ensure price compliance at the retail level through revised price lists and public communication.

Apollo Hospitals to acquire IFC stake in AHLL for Rs 1,254 crore; announces Rs 573 crore oncology investment in Gurugram

BUSINESS

Apollo Hospitals to acquire IFC stake in AHLL for Rs 1,254 crore; announces Rs 573 crore oncology investment in Gurugram

AHLL consists primary care and diagnostics, birthing & women’s Health (Apollo Cradle), ambulatory care centers, dialysis & dental networks.

Genomics major lllumina bets on India to power affordable innovation amid global headwinds

BUSINESS

Genomics major lllumina bets on India to power affordable innovation amid global headwinds

"India is not just a cost center—it’s becoming a core innovation engine for us," said Ankur Dhingra, Chief Financial Officer of Illumina told Moneycontrol.

Dr. Reddy's acquires J&J's Stugeron brand for $50.5 million

BUSINESS

Dr. Reddy's acquires J&J's Stugeron brand for $50.5 million

The acquisition is a strategic move to strengthen Dr. Reddy's Central Nervous System (CNS) portfolio and expand into the anti-vertigo segment.

GST rate cut to spur broader access and market growth of Indian pharma market

BUSINESS

GST rate cut to spur broader access and market growth of Indian pharma market

The sector, which recorded an 8.7% value growth in August 2025, is now bracing for a broader transformation in pricing, access, and patient volumes.

Eye care chain ASG Hospitals accelerates expansion with IPO plans, eyes 700+ centres across India

BUSINESS

Eye care chain ASG Hospitals accelerates expansion with IPO plans, eyes 700+ centres across India

The company is also preparing for a potential IPO within 18–24 months, as it consolidates its position in tier-2 and tier-3 cities and deepens its footprint in underserved districts.

GSK working on affordable vaccines for neglected diseases, partnership with India key: Jamila Louahed

BUSINESS

GSK working on affordable vaccines for neglected diseases, partnership with India key: Jamila Louahed

Jamila Louahed - VP, Head Global R&D for Therapeutic Vaccines and Belgium R&D Site Head for GSK outlined how the pharma major's innovations are being deployed to tackle diseases like malaria, typhoid, tuberculosis, and Shigella.

Somerset Indus Capital Partners nears $250 million close for 3rd healthcare fund

BUSINESS

Somerset Indus Capital Partners nears $250 million close for 3rd healthcare fund

The fund, which focuses on expanding healthcare access to underserved tier 2 and 3 cities, has drawn commitments from a diverse mix of institutional investors

Delhi chemists want 3-month window to clear pharma stock after GST cut

BUSINESS

Delhi chemists want 3-month window to clear pharma stock after GST cut

The Retail Distribution Chemist Alliance has sought immediate relief after GST on medicines was reduced to 5% from 12%, creating an inventory crisis for pharmacies holding stock purchased at the higher rate

Zydus Life arm reports positive phase-3 trial results in rare liver disease, eyes USFDA nod in 2026

BUSINESS

Zydus Life arm reports positive phase-3 trial results in rare liver disease, eyes USFDA nod in 2026

The Ahmedabad-based drugmaker plans to file for USFDA approval in the first quarter of 2026, targeting a market projected to reach $10.8 billion by 2026, growing at a CAGR of 36.3%.

AHPI asks insurers to resume cashless services, ready to review its advisory

BUSINESS

AHPI asks insurers to resume cashless services, ready to review its advisory

"In view of the discussions today, AHPI urged the insurers that they must immediately restore cashless services at its member hospitals, as the disruption is placing an unfair financial and emotional burden on patients," the association said in a statemen

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347